Inovio Pharmaceuticals, Inc. has announced its newest DNA-based cancer immunotherapy targeting melanoma induced a robust and broad immune response in animals and directed cancer-killing T cells against tumors. These results further demonstrate the power and utility of Inovio’s synthetic DNA-based immunotherapy platform focused on cancers and challenging infectious diseases.
In this study, Inovio developed a synthetic DNA immunotherapy encoding the tyrosinase gene which is highly expressed in nearly 80% of melanoma tumor cells. Researchers found in mice that the tyrosinase-targeting DNA immunotherapy was very effective in infiltrating the tumor site, where it prevented tumors, controlled tumor growth, and changed the tumor micro-environment by “turning off” cells that suppress T-cell activity. Inovio’s therapy also increased survival in melanoma-challenged mice versus a control group.
READ FULL ARTICLE
From Medical News Today